Optimizing the Transition to Biosimilars: Considerations for Payers

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.